ARTICLE | Top Story
TKTX, GENZ receive EU approval for Fabry
August 3, 2001 7:00 AM UTC
Transkaryotic Therapies and Genzyme both received European Union marketing approval for their respective therapies for long-term enzyme replacement in patients with Fabry disease. TKTX's Replagal agal...